These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 31813444)

  • 1. Adverse drug reactions in tuberculosis and management.
    Prasad R; Singh A; Gupta N
    Indian J Tuberc; 2019 Oct; 66(4):520-532. PubMed ID: 31813444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse drug reactions & drug interactions in MDR-TB patients.
    Gupta A; Kumar V; Natarajan S; Singla R
    Indian J Tuberc; 2020 Dec; 67(4S):S69-S78. PubMed ID: 33308674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients.
    Ahmad N; Javaid A; Syed Sulaiman SA; Afridi AK; Zainab ; Khan AH
    Am J Ther; 2018; 25(5):e533-e540. PubMed ID: 26938643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.
    Rupani MP; Dave JD; Parmar VB; Singh MP; Parikh KD
    Natl Med J India; 2020; 33(1):10-14. PubMed ID: 33565479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of adverse drug reactions in drug resistant tuberculosis from Punjab.
    Bhushan B; Chander R; Kajal NC; Ranga V; Gupta A; Bharti H
    Indian J Tuberc; 2014 Oct; 61(4):318-24. PubMed ID: 25675695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Longer the Therapy, the Worse the Severity of the Adverse Drug Reactions that Occur in Drug-Resistant Pulmonary Tuberculosis Patients.
    Susilo R; Azzahra DN; Indawati I; Bachtiar A; Setyaningsih I; Rohadi D; Tomi ; Kustini
    Indian J Tuberc; 2024; 71 Suppl 1():S97-S100. PubMed ID: 39067964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rates and risk factors for nephrotoxicity and ototoxicity among tuberculosis patients in Tbilisi, Georgia.
    Buziashvili M; Mirtskhulava V; Kipiani M; Blumberg HM; Baliashvili D; Magee MJ; Furin JJ; Tukvadze N; Kempker RR
    Int J Tuberc Lung Dis; 2019 Sep; 23(9):1005-1011. PubMed ID: 31615608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS).
    Xia YY; Hu DY; Liu FY; Wang XM; Yuan YL; Tu DH; Chen YX; Zhou L; Zhu LZ; Gao WW; Wang HY; Chen da F; Yang L; He PP; Li XT; He YJ; Sun F; Zhan SY
    BMC Public Health; 2010 May; 10():267. PubMed ID: 20492672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tuberculosis drugs adverse reactions: a review of the Iranian literature.
    Kargar M; Mansouri A; Hadjibabaie M; Javadi M; Radfar M; Gholami K
    Expert Opin Drug Saf; 2014 Jul; 13(7):875-91. PubMed ID: 24935479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: A retrospective multicenter study.
    Mishra G; Alffenaar JW; Munje R; Khateeb S
    Indian J Tuberc; 2024; 71 Suppl 1():S101-S109. PubMed ID: 39067941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis.
    Prasad R; Singh A; Srivastava R; Hosmane GB; Kushwaha RA; Jain A
    Indian J Tuberc; 2016 Apr; 63(2):106-14. PubMed ID: 27451820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.
    Rose PC; Hallbauer UM; Seddon JA; Hesseling AC; Schaaf HS
    Int J Tuberc Lung Dis; 2012 Dec; 16(12):1588-93. PubMed ID: 23032215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and Risk Factors Associated with Adverse Drug Reactions among Previously Treated Tuberculosis Patients in China.
    Han XQ; Pang Y; Ma Y; Liu YH; Guo R; Shu W; Huang XR; Ge QP; DU J; Gao WW
    Biomed Environ Sci; 2017 Feb; 30(2):139-142. PubMed ID: 28292352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study.
    Dela AI; Tank NKD; Singh AP; Piparva KG
    Lung India; 2017; 34(6):522-526. PubMed ID: 29098997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and outcomes of adverse drug reactions to first-line anti-tuberculosis drugs and their effects on the quality of life: A multicenter prospective cohort study.
    Choi H; Park HA; Hyun IG; Kim JH; Hwang YI; Jang SH; Sim YS; Shin TR; Ko Y; Ban GY; Hong JY; Lee CY; Lee MG; Choi JH
    Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1153-1163. PubMed ID: 35909258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa.
    Schnippel K; Firnhaber C; Berhanu R; Page-Shipp L; Sinanovic E
    Int J Tuberc Lung Dis; 2018 Apr; 22(4):393-398. PubMed ID: 29562986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.